Two new federal programs are expanding Medicare and Medicaid coverage for GLP-1 obesity drugs, with Tracy Zvenyach of the Obesity Action Coalition discussing implications for primary care physicians and patients.
Two new federal programs are opening Medicare and Medicaid coverage for GLP-1 obesity drugs. Tracy Zvenyach, Ph.D., M.S., RN, of the Obesity Action Coalition, explains what the change may mean for primary care physicians and their patients, though further details were not reported in source.
Personalise this feed
Your specialty. Your sources. Your digest.
All set up in under 2 minutes.
Personalise this feed
Your specialty. Your sources. Your digest.
All set up in under 2 minutes.